Celgene's IBD Franchise Boosted by Otezla Ulcerative Colitis Success

The big-selling psoriasis drug has achieved healthy clinical remission rates in a Phase II trial for ulcerative colitis, and Celgene believes Otezla and another potential blockbuster, ozanimod, will help it build a significant presence in inflammatory bowel disease.

SC1802_Lego Wall_658035112_1200.jpg
Celgene is building a presence in IBD • Source: Shutterstock

Celgene Corp.'s hopes of becoming a force in inflammatory bowel disease have been helped by positive results from a mid-stage trial evaluating its psoriasis blockbuster Otezla (apremilast) for ulcerative colitis (UC).

The biotech major has advanced plans to initiate a Phase III program for Otezla 30 mg in UC on the...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Alimentary/Metabolic

More from Therapy Areas

Genentech Gets Columvi Complete Response Following ODAC’s No

 
• By 

Seeking to move Columvi into second-line DLBCL, Genentech got an FDA letter saying the Phase III STARGLO study’s benefits may have been driven by results in Asian enrollees.

BMS’s Reblozyl Misses Primary Endpoint In Myelofibrosis Anemia

 

The drugmaker announced topline results from the Phase III INDEPENDENCE trial, which did meet key secondary endpoints.

Insmed’s New R&D Site Focused On ‘Synthetic Rescue’

 

A new small-molecule approach to turning on beneficial genes to counteract disease-causing mutations is being pioneered by Insmed’s UK-based scientists.